“For researchers conducting RNA-based assays, the quality of RNA within tissue samples is critical for obtaining accurate and reproducible results,” says Vidyodhaya Sundaram, PhD, MBA, Vice President of Business Development: Oncology, Liquid Biopsy, Early Cancer Detection and Spatial biology at BioChain . “By using qRNA tissue sections, they can eliminate concerns about RNA degradation, save time and resources, and enhance the reliability of their experimental outcomes. By combining BioChain’s extensive biorepository with Molecular Instruments’ state-of-the-art detection technologies, we’re providing an essential resource for researchers who rely on precise and reliable RNA-based data”
The partnership between BioChain and Molecular Instruments brings together leading expertise in biosample quality assurance and advanced RNA detection technologies. The RNA-ISH Verified Tissue product sets a new standard for biosample integrity through rigorous quality control protocols. Each tissue sample undergoes comprehensive RNA integrity validation, ensuring reliable, high-quality RNA for diverse research and diagnostic workflows.
The validated tissue samples are tailored for a range of advanced applications, including:
- RNA sequencing (RNA-Seq)
- In situ hybridization (ISH)
- Gene expression profiling
- Molecular diagnostics
“Collaborating with BioChain advances our mission of bringing clinical-grade assay performance to all research users. Developing next-generation assays requires working with sample tissue that is both high quality and easily validated,” said Dr. Aneesh Acharya, Chief Commercial Officer at Molecular Instruments. “We’re thrilled to partner with BioChain to drive an initiative to improve the quality of clinically relevant research across the industry.”
Researchers using RNA-based methods often need help with tissue quality, sample degradation, and unreliable RNA yields, which can compromise the validity of their results. RNA-ISH Verified Tissue products are designed to eliminate these obstacles by offering tissue samples that are fully assessed for RNA integrity, enabling more reliable and reproducible results across a range of molecular biology applications.
BioChain Institute and Molecular Instruments are committed to advancing scientific discovery by providing the pharmaceutical industry with best-in-class tools. This co-branded initiative reflects both companies’ dedication to fostering innovation in life sciences, biotechnology, and clinical research.
For more information on the HCR™ Verified Tissue products, please visit this website or www.hcrimaging.com.
About BioChain Institutes, Inc.
Trusted by the top 500 global pharmaceutical, biotechnology, and academic leaders for over 25 years, BioChain’s biggest advocates are our customers. Advancing accurate disease diagnosis and drug discovery for biomedical professionals, BioChain is here for you every step of the way with high-quality biospecimens, kits, reagents, instruments, and services. To learn more about the company, visit www.biochain.com
About Molecular Instruments, Inc.
Molecular Instruments® (MI) develops and synthesizes kits powered by its innovative HCR™ Platform for bioimaging applications in academic research, drug development, and clinical pathology and diagnostics. MI offers products for automated and manual chromogenic and fluorescence in situ hybridization (ISH) assays, featuring a protease-free workflow, native compatibility with existing IHC/IF assays, and straightforward image analysis. HCR™ Products are designed to be accessible to all researchers with complimentary introductory Starter KIts, free custom probe design, and pricing that makes sense. To learn more about the company, visit www.hcrimaging.com.
Media Contact
Allyson Markey, BioChain Institute Inc., 1 8582471805, [email protected], https://www.biochain.com/
SOURCE BioChain Institute Inc.
